We are international
Donate
TEXT SIZE   

ask_dr_durie_banner

 

Have a question? Submit it to AskDrDurie@myeloma.org!
 

facebook
googleplus
twitter
youtube


We take questions every week - all are important, however Dr. Durie can only answer so many... so email us - as well as connect with us via one of the social media channels listed above - and we will get it to Dr. Durie!

Our archives are brimming with useful information directed at - and asked by - patients, caregivers, and other interested parties... so please watch the episodes below, and share them as much as possible so that others may benefit!


 

 

 

#Ask Dr. Durie
previous     next      view all

10.30.14   #AskDrDurie: Is it possible to have short remissions without high-risk features?

Inspired by last week's #AskDrDurie episode in which Dr. Brian Durie of the IMF explained the definition of remission when it comes to  myeloma patients, this new episodes is a follow-up. Here, Dr. Durie explains why a myeloma patient might experience a short remission period, even if high-risk features have not been identified.


10.23.14   #AskDrDurie: What is remission?

In the latest episode of #AskDrDurie, Dr. Brian Durie of the IMF explains what remission means for myeloma patients.


10.16.14   #AskDrDurie: How does the IMF contribute to the myeloma community?

In the latest episode of #AskDrDurie, Dr. Brian Durie addresses a patient who has just learned about the IMF by explaining three key contributions the IMF makes to myeloma research and education.


09.25.14   #AskDrDurie: What is Selinexor

In this week's episode of #AskDrDurie, Dr. Brian Durie of the IMF takes a question from a patient who has relapsing myeloma and is wondering about the new drug Selinexor. Dr. Durie explains what the drug is and how it can be used in myeloma.


09.18.14   #AskDrDurie: Is autologous stem cell transplant still recommended?

In this episode of the IMF’s #AskDrDurie web series, Dr. Brian Durie talks about when and for what kind of myeloma patient an autologous stem cell transplant (ASCT) is recommended.


09.10.14   #AskDrDurie: Has there been any change in recommendations used to treat bone disease in myeloma?

In this week's episode of #AskDrDurie, the IMF's Chairman Dr. Brian Durie answers a patient's question regarding how bone disease in myeloma is treated. He discusses bisphosphonates such as Aredia and Zometa and what the current recommendations are.


09.03.14   #AskDrDurie: If Pomalyst does not produce a full response, what are my options?

In this episode of #AskDrDurie, Dr. Brian Durie explores options for myeloma treatment if a patient isn’t receiving a full response from Pomalyst.


08.27.14   #AskDrDurie: Is there a test available for measuring Minimal Residual Disease, what we call MRD?

In this week's #AskDrDurie, the IMF's Dr. Brian Durie answers a very important question regarding the tests available for measuring Minimal Residual Disease. As you may know, the IMF's Black Swan Research Initiative(R) has been evaluating a new flow test method for this, and it is becoming a new benchmark.


08.13.14   #AskDrDurie: How can Revlimid’s diarrhea side effect be handled?

In this episode of #AskDrDurie, the IMF's Dr. Brian Durie answers a patient's question about dealing with a specific side effect from Revlimid.


08.07.14   #AskDrDurie: Is it okay to take vitamin B12 on the same day as Velcade?

In this episode of #AskDrDurie, Dr. Brian Durie of the IMF answers a myeloma patient’s question about taking a supplement like vitamin B12 on the same day as Velcade.


previous     next      view all